FDA Awards Breakthrough Therapy Designation to Ensysce Biosciences' PF614-MPAR: A Leap Forward in Opioid Innovation.
FDA Designation Announced For First Ever Oral Opioid Overdose Drug
FDA Designation Announced For First Ever Oral…
FDA Designation Announced For First Ever Oral Opioid Overdose Drug
FDA Awards Breakthrough Therapy Designation to Ensysce Biosciences' PF614-MPAR: A Leap Forward in Opioid Innovation.